Home > Healthcare > Pharmaceuticals > Finished Drug Form > Trachoma Treatment Market

Trachoma Treatment Market Trends

  • Report ID: GMI9128
  • Published Date: Apr 2024
  • Report Format: PDF

Trachoma Treatment Market Trends

  • The high prevalence of trachoma serves as a significant growth driver for the market. Trachoma is a leading cause of preventable blindness globally, particularly in low-resource settings with poor sanitation and limited access to healthcare.
     
  • For instance, as per the Pan American Health Organization (PAHO), globally, in April 2023, an estimated 115.7 million people lived in areas where the prevalence of trachoma in children aged 1 to 9 years was ≥5%. Further, the estimated global burden of trachomatous trichiasis in 2023 was 1.5 million cases.
     
  • This high prevalence has led to increased efforts by governments, non-profit organizations, and pharmaceutical companies to develop and distribute treatments, driving the growth of the market.
     
  • Thus, as awareness of the disease grows and initiatives to eliminate trachoma gains momentum, the market is expected to expand further, addressing the significant unmet medical need in affected communities.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global trachoma treatment market was valued at USD 532.4 million in 2023 and is anticipated to grow at 5.9% CAGR between 2024 – 2032, driven by continuous efforts of various organizations and governments to eliminate trachoma as a public health problem.

The hospital pharmacy segment is anticipated to reach USD 475.9 million by 2032, due to their ability to offer centralized access to medications for patients undergoing treatment for trachoma.

North America trachoma treatment market is anticipated to reach USD 352.6 million by 2032, attributed to robust government initiatives and funding for healthcare, along with strong support from non-governmental organizations.

AstraZeneca, Bausch Health Companies Inc., Bayer AG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Ltd.

Trachoma Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 264
  • Countries covered: 22
  • Pages: 150
 Download Free Sample